UAE Cardiovascular Diseases Therapeutics Market Report 2022 to 2030

UAE Cardiovascular Diseases Therapeutics Market Analysis

$ 3999

UAE's cardiovascular disease therapeutics market is projected to grow from $813 Mn in 2022 to $1,530 Mn in 2030 with a CAGR of 8.22% for the year 2022-30. The rise in sedentary lifestyles adopted by the UAE citizens and the technological advancement of cardiovascular therapeutics in the UAE are responsible for the growth of the market. The UAE cardiovascular disease therapeutics market is segmented by disease indication, drug type, route of administration, drug classification, mode of purchase, and end user. Lumitive, Hikma Pharmaceuticals, and F. Hoffmann-La Roche are the major players in the UAE cardiovascular disease therapeutics market.

ID: IN10AEPH033 CATEGORY: Pharmaceuticals GEOGRAPHY: UAE AUTHOR: Dr. Parul Choudhary

Buy Now

UAE Cardiovascular Disease Therapeutics Market Executive Analysis

UAE's cardiovascular disease therapeutics market is projected to grow from $813 Mn in 2022 to $1,530 Mn in 2030 with a CAGR of 8.22% for the year 2022-30. The future holds growth for Dubai's healthcare industry. According to the Dubai Chamber of Commerce and Industry, revenue generated within the overall UAE healthcare sector is anticipated to increase by 7.5% annually to hit $10.7 Bn by 2025. Meanwhile, it is anticipated that healthcare expenditure will increase to 4.6% of GDP by 2026 and 5.1% of GDP by 2029. With increased government initiatives, the UAE healthcare industry is expanding at an astounding rate. Additionally, the UAE government is significantly enhancing and extending its healthcare system in order to create a powerful, top-notch healthcare infrastructure. To improve the current infrastructure and match the caliber of services provided in developed nations, the government is also encouraging private sector involvement.

According to a Ministry of Health and Prevention study, Cardiovascular Disease (CVD) is the main cause of death in the UAE. Acute myocardial infarction (AMI), cerebrovascular disease, ischaemic heart disease, and hypertension were each responsible for 16%, 22%, 6%, and 5% of CVD fatalities, respectively. The most successful interventions, according to the WHO's report, include drug therapy, laws restricting alcohol and tobacco use, health counseling, and public awareness campaigns that encourage frequent exercise and a balanced diet. Effective prevention strategies are understood to be developed, put into action, and monitored on the premise of a better understanding of the epidemiology, prevalence, and risk factors of CVD.

In the UAE, statin treatment is the most popular method for removing clots and restoring the elasticity of the endothelial membrane in blood arteries. Aspirin is also the most commonly prescribed medication for the secondary protection of CVDs. As an alternative, -adrenergic receptor blockers are also recommended as first-choice treatments for coronary artery disease and atrial fibrillation, but they are not used as first-line therapy for hypertension. Treatment for hypertension, congestive heart failure, and myocardial infarction also includes the use of ACE inhibitors and ARBs, which suppress the angiotensin-II receptor. In addition to the more established renin-angiotensin II receptor blockers, novel candidates like sacubitril/valsartan (an angiotensin receptor-neprilysin inhibitor) were explored as more effective treatments to lower mortality in patients with low ejection fraction cardiac failure, but clinical trials are still ongoing in the UAE.

UAE Cardiovascular Disease Therapeutics Market Analysis

Market Dynamics

Market Growth Drivers

With a rise in sedentary employment and a decline in physical exercise, the UAE has seen significant changes in lifestyle over the past few decades. As a result, the prevalence of cardiovascular illnesses has increased, increasing the need for treatments. Cardiovascular disease therapeutics have benefited greatly from technical advancements, which have sparked an influx of new, more effective medications. As a result, there is no more desire for such products in the UAE cardiovascular disease therapeutics market.

Market Restraints

Cardiovascular disease therapeutics can be expensive, rendering them unaffordable for many patients. This may limit the expansion of the UAE cardiovascular disease therapeutics market. Some treatments for cardiovascular disease may have unfavourable side effects that restrict their use, lowering consumer desire for these goods. With many generic medications readily accessible, the market for cardiovascular disease therapeutics in the UAE is extremely competitive. There may be less desire for branded products as a result of these goods being less expensive than name-brand medications.

Competitive Landscape

Key Players

MPC Healthcare (ARE)
Elis Pharmaceuticals (ARE)
Pharmatrade (ARE)
Lumitive (ARE)
Hikma Pharmaceuticals (ARE)
F. Hoffmann-La Roche
Fresenius Kabi
Bayer
Sun Pharmaceutical
Novartis
Mylan

Healthcare Policies and Regulatory Landscape

A National Cardiovascular Disease Prevention and Control Program has been initiated by the UAE Ministry of Health and Prevention. The program's primary goals are early detection, prevention, and treatment of cardiovascular diseases. All UAE citizens and inhabitants now have access to affordable healthcare services thanks to the National Health Insurance Program that the UAE government has put in place. The treatments for cardiovascular illness are included in the program's extensive list of services. The UAE Ministry of Health and Prevention advises routine cardiovascular disease monitoring for all UAE citizens. The early detection and prevention of cardiovascular diseases are aided by this. Through its national health insurance scheme, the UAE government pays for some medications for cardiovascular disease. In order to enhance healthcare services and increase access to cutting-edge treatments for cardiovascular illness, the UAE government promotes public-private partnerships.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Cardiovascular Disease Therapeutics Segmentation

By Disease Indication (Revenue, USD Billion):

Hypertension
Coronary Artery Disease
Hyperlipidaemia
Arrhythmia
Others

By Drug Type (Revenue, USD Billion):

Antihypertensive
Anticoagulants
Antihyperlipidemic
Antiplatelet Drugs
Others

By Route of Administration (Revenue, USD Billion):

Oral
Parenteral
Others

By Drug Classification (Revenue, USD Billion):

Branded Drugs
Generic Drugs

By Mode of Purchase (Revenue, USD Billion):

Prescription-Based Drugs
Over-The-Counter Drugs

By End Users (Revenue, USD Billion):

Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.